Earlier intensified insulin treatment of Type 1 diabetes and its association with long-term macrovascular and renal complications

Diabetic Medicine : a Journal of the British Diabetic Association
B RathsmanT Nyström

Abstract

To investigate the incidence of all-cause mortality, composite mortality and morbidity in people with Type 1 diabetes formerly randomized in the Stockholm Diabetes Intervention Study. A total of 102 people with Type 1 diabetes were randomized in the period 1982-1984 to intensified conventional treatment or standard treatment with insulin for a mean of 7.5 years. We prospectively re-evaluated this cohort for the period until 2011 with regard to all-cause mortality and composite mortality, which consisted of myocardial infarction, stroke and end-stage renal disease as primary endpoints. Secondary endpoints were first-time hospitalization for myocardial infarction and stroke or end-stage renal disease. Data on HbA1c levels (mean of 22 values/person) were retrospectively collected between 1996 and 2011. During the median follow-up of 28 years, 22 people died: seven in the intensified conventional insulin group compared with 15 in the standard treatment group (P = 0.30). With regard to composite mortality, six people in the intensified conventional insulin group died compared with 11 in the standard treatment group (P = 0.56). For the secondary endpoints, 11 people in the intensified conventional insulin group developed myocardial i...Continue Reading

References

Nov 1, 1985·Kidney International·O ShemeshB D Myers
Jan 1, 1988·Acta Medica Scandinavica·P ReichardU Rosenqvist
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Sep 28, 1996·BMJ : British Medical Journal·P RossingH H Parving
Mar 29, 2003·Diabetes Care·Soffia GudbjörnsdottirUNKNOWN Steering Committee of the Swedish National Diabetes Register
Jul 16, 2003·Annals of Internal Medicine·Andrew S LeveyUNKNOWN National Kidney Foundation
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Apr 30, 2009·Diabetes·Per-Henrik GroopUNKNOWN FinnDiane Study Group
Mar 3, 2011·Acta Neurologica Scandinavica·P Appelros, A Terént
Jun 11, 2011·BMC Public Health·Jonas F LudvigssonPetra Otterblad Olausson
Nov 15, 2011·The New England Journal of Medicine·UNKNOWN DCCT/EDIC Research GroupBernard Zinman
Nov 13, 2013·Clinical and Experimental Nephrology·Andrzej S KrolewskiMonika A Niewczas
Apr 18, 2014·The New England Journal of Medicine·Edward W GreggLinda Geiss
Jun 14, 2014·Journal of the American Society of Nephrology : JASN·Ian H de BoerUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group
Jan 7, 2015·JAMA : the Journal of the American Medical Association·UNKNOWN Writing Group for the DCCT/EDIC Research GroupJohn M Lachin

❮ Previous
Next ❯

Citations

Apr 14, 2016·Journal of Diabetes and Its Complications·Semiha TerlemezBülent Çelik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.